Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;14(6):e200346.
doi: 10.1212/CPJ.0000000000200346. Epub 2024 Aug 16.

An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation

Katherine W Turk  1 , Mark D Knobel  1 , Alexandra Nothern  1 , Garrett Friedman  1 , Hannah Noah  1 , Brendan Campbell  1 , Diana C Anderson  1 , Andreas Charidimou  1 , Andrew Mills  1 , Vanessa Coronel  1 , Nacha Pierre  1 , Beverly V Reynolds  1 , Caroline Wagner  1 , Leanne M Varga  1 , John Roefaro  1 , Laura Triantafylidis  1 , Andrew E Budson  1
Affiliations

An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation

Katherine W Turk et al. Neurol Clin Pract. 2024 Dec.

Abstract

Background: Lecanemab and other new amyloid-targeting immunotherapies for Alzheimer disease show notable promise but may also pose significant risk for patients.

Recent findings: To facilitate the implementation and monitoring of lecanemab infusions at our tertiary medical center, we convened an interprofessional team. The team created a number of resources including patient handouts and medical documentation templates as well as systems and processes that are likely to be useful to other clinical care settings and centers.

Implications for practice: It is our intent to widely share the resources and processes developed.

PubMed Disclaimer

Conflict of interest statement

K.W. Turk reports research funding from the Alzheimer's association, US Department of Veterans Affairs, the Doris Duke Foundation and Vox Neuro incorporated. A.E. Budson reports Eli Lilly: Consultant, VoxNeuro: investigator initiated grant, Bristol Myers Squbb: investigator initiated grant, Oxford University Press: author royalties. Elsevier: author royalties. The other authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.TAKE-HOME POINTS→ An interdisciplinary team was assembled to facilitate the initial rollout of disease modifying therapies for AD.→ The team developed patient-facing and internal documents to streamline initial medication roll out effectively.→ The team also developed policies, procedures, and weekly review processes for initial eligibility screening.→ The team has developed processes for ongoing imaging and clinical review of patients receiving infusions.→ Processes and resources developed are being disseminated for use and adaptation by others.

References

    1. van Dyck CH, Swanson CJ, Aisen P, et al. . Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948 - DOI - PubMed
    1. Vives-Rodriguez AL, Schiloski KA, Marin A, et al. . Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic. Alzheimers Dement (N Y). 2022;8(1):e12320. doi:10.1002/trc2.12320 - DOI - PMC - PubMed
    1. Roytman M, Mashriqi F, Al-Tawil K, et al. . Amyloid-related imaging abnormalities: an update. AJR Am J Roentgenol. 2023;220(4):562-574. doi:10.2214/AJR.22.28461 - DOI - PubMed
    1. Lofy M, Jung L, Dow-Hillgartner E. Premedication strategy in cetuximab rechallenge after grade 2 hypersensitivity reactions. J Oncol Pharm Pract. 2024;30(2):412-416. doi:10.1177/10781552231212640 - DOI - PubMed

LinkOut - more resources